Blood Sample

PharmaLundensis AB (publ) develops the following projects:
* A new, effective treatment for chronic obstructive pulmonary disease, COPD.
* EcoFilter® which prevents the release of antibiotics and multi-resistant bacteria in hospital waste water.
* An effective treatment for chronic bronchitis.
* Treatment for influenza-induced lung failure.

PharmaLundensis shares are traded on Aktietorget

Successful development of new, high quality Iodocarb (29 january 2018)
Over the past year, PharmaLundensis has carried out a process to further develop the method of production of the company’s drug candidate, Iodocarb, for treatment of chronic obstructive pulmonary disease (COPD). The aim was to obtain a significant reduction in the release of iodine from the substance while retaining the full effect of binding mercury. This substance can be expected to show the same positive effects on lung capability that were shown in the company’s first COPD study, but without any side effects in the thyroid. This development process has now been completed successfully.

The new iodated carbon, Iodocarb Novum, releases around 70% less iodine at all iodine levels (3%, 6% and 9%) compared with the old iodated carbon, see Fig 1 below. The mercury-binding capability is at least as good, or better, see Fig 2 below.

CEO Dr Staffan Skogvall: “The new iodated carbon provides a significantly reduced release of iodine compared with the old iodated carbon, while the mercury-binding capability is at least as good. I consider that we have therefore solved the problems relating to the side effects in the thyroid. In 2018 we plan to initiate two new clinical studies for Iodocarb Novum. We will also end the current study concerning Iodocarb comp, because the new iodated carbon releases so little iodine that there is no need for adding perchlorate. Performing clinical studies with a drug that only contains iodated carbon (without perchlorate) will significantly simplify the registration process. Another advantage with the new iodated carbon is that it can be protected as a new patent family. We can therefore maintain patents in many countries where we currently do not have patent protection, and strengthen our protection in the countries where we do currently have approved patents.”

In summary I consider that the development of the new, high-quality Iodocarb Novum is an important milestone for our COPD project. It can be the key to success for this project!  

Fig 1: Release of iodine from new (blue) and old type of Iodocarb.

Fig 1

Fig 2: Mercury binding capacity in new (blue) and old type of Iodocarb.

Fig 2

Approved Swedish Trademark Registration (22 Nov 2017)
The Swedish Patent and Registration Office (PRV) has announced that it has approved “Bronkitstopp PharmaLundensis” as a trademark. The trademark applies to Group 5 (Pharmaceuticals) and Group 10 (Medical Devices and Instruments). Trademark registration is valid for up to 10 years. Registration Number: 542356.

CEO Dr Staffan Skogvall: “PharmaLundensis´ various projects continue to develop well, and now the name of the medical device that treats chronic bronchitis has been approved. As described in the recently published quarterly report (16 November 2017), we are awaiting the result of the ongoing adjustment of the production of iodinated activated charcoal before we submit the Bronkitstopp registration application.”

Q3 Quarterly Report published (16 Nov 2017)
PDF: Q3 2017 Report

Share acquisition by CEO (13 oct 2017)
Staffan Skogvall has recently acquired 4 221 PharmaLundensis shares. During 2017 he has purchased a total of 22 511 PharmaLundensis shares.

Patent for the treatment of chronic bronchitis is granted in Europe (170921)
The European Patent Office (EPO) has announced that it approves PharmaLundensis patent application entitled “Activated carbon comprising an adsorbed iodide salt in a method for treating chronic bronchitis WO2014084763. The patent is valid until 2032 with the option of a 5 year extension.

A patent for this project has previously been granted in Japan and applications are currently being assessed in China and South Korea.

CEO Dr Staffan Skogvall: “PharmaLundensis´patent portfolio is developing very well. Recently, the first national patent for the COPD treatment Iodocarb comp was granted and now the patent that protects the treatment of chronic bronchitis has been approved on the company’s main market in Europe. I am pleased that the patent authorities understand and approve our innovative products!”

Licensing (15 Sept 2017)
PharmaLundensis participated in the Nordic Life Science Days 2017. During this partnering event we met a number of pharma companies from Japan, South Korea and India who had requested information about PharmaLundensis´COPD  treatment Iodocarb. All the companies expressed an interest in the project after the meeting and requested additional information for their internal discussions.

The meetings fit well into PharmaLundensis´strategy to retain marketing rights on core markets (Europe) while licensing Iodocarb to local partners elsewhere. The pharma companies were of a medium size with around 500-2,000 people in their pharma divisions. All the companies have experience in clinical trials and registering new substances on their markets. This is important since a COPD treatment developed exclusively with European patients will need to have some additional clinical studies performed on Asian patients before registration in those countries can be possible.  We intend to license Iodocarb exclusively to one pharma company on each market outside Europe.

First patent for Iodocarb comp granted (8 Sept 2017)
PharmaLundensis patent application protecting activated carbon impregnated with iodine or iodine salts in combination with perchlorate (Iodocarb comp WO2015075111) for treatment of chronic obstructive pulmonary disease (COPD) has now been granted in South Africa. The patent lasts for at least 16 years, with the possibility of a 5 year extension.

This is the first patent for Iodocarb comp that has been granted. PharmaLundensis has also filed national patent applications  in nine other markets (USA, Europe, China, Japan, Chile, Israel, Saudi Arabia, South Korea and Russia). As described in the Year-end Report, February 16, 2017, the company has the strategy of securing patent protection in the four major markets (EU, US, Japan and China), but also in at least one smaller country per continent outside the major markets. The plan is that a pharmaceutical company in that country licenses Iodocarb comp and then is responsible for sales across the region. A pharmaceutical company in South Africa will thus be responsible for the sale of Iodocarb in the majority of the African countries.

CEO Dr Staffan Skogvall: “It is very positive that the first national patent for Iodocarb comp is now granted. There is  therefore a great likelihood of positive results in other regions. I think we will benefit greatly from this patent, which will also be able to protect the new, improved iodinated carbon that we are developing.”

Development of new, more effective Iodocarb
PharmaLundensis is developing a new iodinated activated charcoal that has the potential to multiply the positive effects on the airways. If this is successful, it can be of great use to all COPD sufferers!

Japanese patent for KI-impregnated activated carbon granted
PharmaLundensis has now received Patent in Japan for potassium iodide impregnated charcoal for treatment of chronic bronchitis:
Japanese KI-patent